{"id":140343,"title":"Archived 34: Summary of NACI statement of March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:14:04.471000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-medicago-covid-19-vaccine/summary-march-11-2022.html?wbdisable=true","snippet":"Archived 34: Summary of NACI statement of March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz) - Canada.ca Skip to main content Skip to \"About government\" We have archived this page and will not be updating it. You can use it for research or…","rawSnapshotUrl":"/api/snapshots/raw/140343","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141404/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-medicago-covid-19-vaccine/summary-march-11-2022.html?wbdisable=true#ha_snapshot=140343","mimeType":"text/html","statusCode":200}